65岁以下肾下腹主动脉瘤解剖条件良好者EVAR长期疗效
该回顾性研究比较了年龄≤65岁、肾下腹主动脉瘤且解剖条件适合EVAR的患者接受EVAR与开放手术修复(OSR)的早期和长期结局。共纳入115例患者(EVAR 58例,OSR 57例),EVAR组ICU入住率、输血量、住院时间及30天内再干预率均低于OSR组,但10年无再干预生存率和总体生存率两组无显著差异。
要点
- EVAR组ICU入住率19% vs OSR组79%(P=0.001),住院时间4±2天 vs 9±6天(P=0.03)。
- EVAR组30天内再干预率0% vs OSR组8%(P=0.001),但10年无再干预率两组无差异(81% vs 74%,P=0.77)。
- OSR组术后逆行射精发生率31% vs EVAR组2%(P=0.001)。
核心结论
- 对于年龄≤65岁、肾下腹主动脉瘤且解剖条件适合EVAR的患者,EVAR与OSR在10年生存率和再干预率上无显著差异。
- EVAR可缩短住院时间、减少ICU需求和早期再干预,但长期再干预风险与OSR相当。
研究设计与样本
- 回顾性研究,纳入2005年至2013年间年龄≤65岁接受肾下腹主动脉瘤修复的患者。
- 共115例患者,其中EVAR组58例(51%),OSR组57例(49%)。
- EVAR均按使用说明书(IFU)执行,OSR仅纳入肾下主动脉阻断的病例。
- 平均随访86±38个月。
主要发现
- EVAR组与OSR组除肥胖外(38% vs 19%,P=0.03),其他合并症相似。
- EVAR组ICU入住率19% vs OSR组79%(P=0.001),输血量236±31 mL vs 744±98 mL(P=0.001),住院时间4±2天 vs 9±6天(P=0.03)。
- 总体30天死亡率为1%(EVAR 0% vs OSR 2%,P=0.30)。
- 30天内再干预5例(4%),EVAR组0% vs OSR组8%(P=0.001)。
- 10年无再干预率EVAR组81% vs OSR组74%(P=0.77);晚期再干预OSR组13例(23%)vs EVAR组10例(17%)。
临床怎么用
- 对于年龄≤65岁、肾下腹主动脉瘤且解剖条件适合EVAR的患者,EVAR可作为开放手术的替代选择,尤其可减少ICU资源使用和缩短住院时间。
- 需告知患者EVAR与OSR的长期再干预率和生存率相似,但EVAR早期再干预更少、性功能保护更优。
局限性
- 回顾性研究设计,样本量较小(115例),可能存在选择偏倚。
- 仅纳入解剖条件适合EVAR且OSR为肾下阻断的患者,结论外推受限。
- 随访时间虽较长,但部分结局事件数较少,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to compare early and long-term outcomes of endovascular aneurysm repair (EVAR) versus open surgical repair (OSR) in patients aged ≤ 65 years. METHODS: Data of patients aged ≤65 years undergoing infrarenal abdominal aortic aneurysm repair, between 2005 and 2013, were retrospectively reviewed. All EVAR procedures were performed according to the instruction for use, and only OSR procedures with an infrarenal aortic cross-clamping were included in the study. RESULTS: In this group of 115 patients (EVAR: 58 patients, 51% and OSR: 57 patients, 49%), EVAR and OSR patients had similar comorbidities, except for obesity (EVAR: 38% vs. OSR: 19%; P = 0.03). A stay in the intensive care unit (ICU) was necessary in 19% of patients with EVAR versus 79% with OSR (P = 0.001), and the amount of blood transfusion was 236 ± 31 mL for EVAR versus 744 ± 98 mL for OSR (P = 0.001). The hospital stay was 4 ± 2 days for EVAR versus 9 ± 6 days for OSR (P = 0.03). The overall 30-day mortality was 1% (EVAR: 0% vs. OSR: 2%; P = 0.30). Five patients (4%) required reinterventions within 30 days (EVAR: 0% vs. OSR: 8%, P = 0.001). The mean follow-up was 86 ± 38 months. Freedom from reintervention at 10 years after EVAR was 81% versus OSR 74%; (P = 0.77). Late reinterventions were reported in 13 patients (23%) with OSR and in 10 patients (17%) with EVAR. Postoperative retrograde ejaculation occurred more often in patients with OSR (31%) versus EVAR (2%) (P = 0.001). During the follow-up, cancer was found in 19 (17%) patients with no difference between EVAR and OSR (P = 0.83). The global survival at 10 years was 72% (EVAR: 79% vs. OSR: 70%; P = 0.94). CONCLUSIONS: In this study, EVAR was associated with a shorter hospital stay, less need for the ICU, and less early reinterventions than OSR. Survival and reinterventions during the follow-up were not significantly different between EVAR and OSR. According to these results, EVAR may be considered for patients aged ≤65 years with a favorable anatomy.
引用
- Gallitto E, Faggioli G, Mascoli C, et al. Long-term Efficacy of EVAR in Patients Aged Less Than 65 Years with an Infrarenal Abdominal Aortic Aneurysm and Favorable Anatomy. Ann Vasc Surg. 2020. PMID: 32283305. doi:10.1016/j.avsg.2020.03.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。